Category: Cardinal Health
Certain laparoscopic surgical kits from CardinalHealth present serious risk of patient harm, the FDA warns.
Updated May 9, 2013, at 2:30 p.m. with a comment from Cardinal Health.
InspireMD nets nearly $23 million from a public stock offering, saying it plans to use the proceeds to pursue U.S. approval of its MGuard coronary and carotid stents.
InspireMD (OTC:NSPR) said it added some $23 million to its coffers in a public stock offering.
The Tel Aviv-based medical device company makes the MGuard device, designed to protect against embolism after stenting procedures.
Cardinal Health says it's agreed to pony up more than $2 billion for medical supplies provider AssuraMed, itself fresh off the M&A trail.
Cardinal Health (NYSE:CAH) said it plans to spend $2.07 billion aquiring medical supplies company AssuraMed, which itself just bought Invacare's supplies business last month.
Cardinal Health's fiscal 2nd-quarter earnings miss Wall Street's target, sending shares down a tick.
Cardinal Health (NYSE:CAH) missed the earnings target set by Wall Street analysts for its fiscal 2nd quarter, sending shares down slightly today.
The Dublin, Ohio, medical device and pharmaceutical company reported profits of $303 million, or 88¢ per share, on sales of $25.23 billion, for bottom-line growth of 15.6% despite a top-line slide of 6.8% compared with the same period in 2011.
Novation picks up new product lines from Teleflex, Covidien and others.
Cardinal Health's medical device arm didn't fare so well during the company's 1st quarter, with profits down on a modest increase in sales.
Cardinal Health (NYSE:CAH) reported disappointing numbers for its medical device business during the company's 1st quarter, citing volume softness that led to a 6% dip in profit.
Medical device revenues amounted to just under $2.4 billion during the 3 months ended Sept. 30, 2012, representing a 1% increase year-over-year.
A California judge tosses PharmaRx Pharmaceuticals' lawsuit accusing GE and Cardinal Health of conspiring to monopolize the market for cardiac imaging agents.